nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil
Company profile
Ticker
NEPH
Exchange
Website
CEO
Andrew Astor
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Biocon 1, LLC • Aether Water Systems, LLC ...
IRS number
133971809
NEPH stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
15 Mar 24
8-K
Nephros Announces Fourth Quarter and Fiscal Year 2023 Financial Results
7 Mar 24
10-Q
2023 Q3
Quarterly report
8 Nov 23
8-K
Departure of Directors or Certain Officers
6 Nov 23
8-K
Second-Quarter Net Revenue of $3.5 Million, a 24% Increase Over 2022; Year-to-Date Revenue Increases 45%; Maintains Positive Cash Flow Results
9 Aug 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
1 Jun 23
8-K
Nephros Announces CEO Retirement and Succession Plan
11 May 23
10-Q
2023 Q1
Quarterly report
10 May 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
Transcripts
NEPH
Earnings call transcript
2023 Q4
7 Mar 24
NEPH
Earnings call transcript
2023 Q3
8 Nov 23
NEPH
Earnings call transcript
2023 Q2
9 Aug 23
NEPH
Earnings call transcript
2023 Q1
10 May 23
NEPH
Earnings call transcript
2022 Q4
8 Mar 23
NEPH
Earnings call transcript
2022 Q3
2 Nov 22
NEPH
Earnings call transcript
2022 Q2
11 Aug 22
NEPH
Earnings call transcript
2022 Q1
7 May 22
NEPH
Earnings call transcript
2021 Q4
24 Feb 22
NEPH
Earnings call transcript
2021 Q3
7 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 4.62 mm | 4.62 mm | 4.62 mm | 4.62 mm | 4.62 mm | 4.62 mm |
Cash burn (monthly) | (no burn) | (no burn) | 67.67 k | 136.42 k | (no burn) | (no burn) |
Cash used (since last report) | n/a | n/a | 381.57 k | 769.24 k | n/a | n/a |
Cash remaining | n/a | n/a | 4.24 mm | 3.85 mm | n/a | n/a |
Runway (months of cash) | n/a | n/a | 62.7 | 28.2 | n/a | n/a |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 185 |
Opened positions | 27 |
Closed positions | 26 |
Increased positions | 76 |
Reduced positions | 59 |
13F shares | Current |
---|---|
Total value | 884.57 bn |
Total shares | 64.66 mm |
Total puts | 2.60 k |
Total calls | 3.10 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
ADTTF Advantest | 33.07 mm | $802.59 mm |
BLK Blackrock | 4.66 mm | $150.88 bn |
Vanguard | 2.93 mm | $94.91 bn |
Kibarian John Kachig | 2.51 mm | $0.00 |
IVZ Invesco | 2.44 mm | $79.12 bn |
Kimon Michaels | 1.62 mm | $13.62 mm |
Snyder Capital Management L P | 1.17 mm | $37.84 bn |
Wasatch Advisors | 1.15 mm | $37.11 bn |
Samjo Capital | 1.10 mm | $35.68 bn |
STT State Street | 1.05 mm | $34.06 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Wexford Capital | Common Stock | Other | Dispose J | No | No | 0 | 91,463 | 0.00 | 56,060 |
13 Mar 24 | Amron Arthur H | Common stock | Other | Acquire J | No | No | 0 | 91,463 | 0.00 | 98,463 |
12 Mar 24 | Amron Arthur H | Common stock | Buy | Acquire P | No | No | 2.4471 | 7,000 | 17.13 k | 7,000 |
13 Dec 23 | Alisa Lask | Common Stock | Grant | Acquire A | No | No | 0 | 9,291 | 0.00 | 48,629 |
13 Dec 23 | Amron Arthur H | Common Stock | Grant | Acquire A | No | No | 0 | 9,291 | 0.00 | 9,291 |
13 Dec 23 | Oliver J. Spandow | Common Stock | Grant | Acquire A | No | No | 0 | 14,294 | 0.00 | 81,604 |
News
Benchmark Upgrades Nephros to Speculative Buy, Announces $5 Price Target
8 Mar 24
Nephros: Q4 Earnings Insights
7 Mar 24
Nephros Q4 2023 GAAP EPS $(0.060) Misses $(0.030) Estimate, Sales $3.300M Miss $3.813M Estimate
7 Mar 24
Earnings Scheduled For March 7, 2024
7 Mar 24
Earnings Outlook For Nephros
6 Mar 24